> 首页 > 产品 > 一抗 > 基因重组 > Anti-LAG3 / CD223 Reference Antibody (relatlimab)

Anti-LAG3 / CD223 Reference Antibody (relatlimab)

Recombinant Antibody

Anti-LAG3 / CD223 Reference Antibody (relatlimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%
The purity of Anti-LAG3 / CD223 Reference Antibody (relatlimab)is more than 100% ,determined by SEC-HPLC.
Immobilized human LAG3 His at 2 µg/mL can bind Anti-LAG3 / CD223 Reference Antibody (relatlimab)，EC50=0.02812 µg/mL.
Human LAG3 CHO cells were stained with Anti-LAG3 / CD223 Reference Antibody (relatlimab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC78=0.5464 ug/mL
Relatlimab inhibited the tumor growth of MC38 on Human LAG3 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 53.8% at 10 mpk at D28.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	FC, Kinetics, Animal Model
Primary Accession	P18627
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	57449 Da

Additional Information
Target/Specificity	LAG3 / CD223
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information
Name	LAG3 {ECO:0000303\|PubMed:35761082, ECO:0000312\|HGNC:HGNC:6476}
Function	[Lymphocyte activation gene 3 protein]: Inhibitory receptor on antigen activated T-cells (PubMed:20421648, PubMed:35761082, PubMed:7805750, PubMed:8647185). Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells (PubMed:30580966, PubMed:32920841, PubMed:35761082, PubMed:39671469, PubMed:7589152, PubMed:8647185, PubMed:9159144). Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed:40101708). Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation (PubMed:40101708, PubMed:40592325). May inhibit antigen- specific T-cell activation in synergy with PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:20421648, PubMed:7805750, PubMed:8647185). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity).
Cellular Location	[Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein. Note=Clusters on the T-cell surface following ligand-binding
Tissue Location	Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.